---
url: https://www.servicesaustralia.gov.au/systemic-lupus-erythematosus-toxicity-and-severity-descriptors
title: Systemic lupus erythematosus toxicity and severity descriptors - Health professionals - Services AustraliaServices AustraliaServices Australia
scrapedAt: 2026-02-20T21:44:05.632Z
source: servicesaustralia.gov.au
---
# Systemic lupus erythematosus toxicity and severity descriptors

Toxicity and severity descriptors for treatments required to be trialled before accessing PBS-subsidised biological medicines to treat systemic lupus erythematosus.

## on this page

-   [Prednisolone](#a1)
-   [Hydroxychloroquine](#a2)
-   [Methotrexate](#a3)
-   [Azathioprine](#a4)
-   [Mycophenolate](#a5)

ALT - alanine aminotransferase  
AST - aspartate aminotransferase  
BP - blood pressure  
ECG - electrocardiogram  
IV - intravenous  
NIH - National Institutes of Health  
ULN - upper limit of normal  
WCC - white cell count

## Prednisolone

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastrointestinal**

Gastric irritation or ulcer

Requiring medical management

2 (or higher)

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Weight gain

≥ 20% weight gain

3 (or higher)

**Cardiovascular**

Hypertension

Requiring therapy or more intensive therapy than previously

3 (or higher)

Fluid retention

Symptomatic, limiting function, unresponsive to therapy or requiring drug discontinuation

3 (or higher)

**Central nervous system**  
past psychiatric history is not a contraindication

Insomnia

Frequent insomnia interfering with activities of daily living

3 (or higher)

Mood alteration

Severe mood alteration interfering with activities of daily living

3 (or higher)

Personality or behaviour

Disruptive to patient or family, requiring mental health intervention

3 (or higher)

Restlessness

Severe

3 (or higher)

**Dermatological**

Acne or dermatological conditions

Severe

3 (or higher)

Purpura or bruising

Generalised or mucosal petechiae

3 (or higher)

Impaired healing

Requiring medical management

2 (or higher)

**Laboratory**

Hyperglycaemia

Glucose 13.9 mmol per L or higher

3 (or higher)

Hypertriglyceridaemia

\> 5-10 x upper limit of normal

3 (or higher)

Hypokalaemia

< 3.0 mmol per L

3 (or higher)

**Endocrine**

Cushingoid appearance

Present

3 (or higher)

Disordered menstruation

Very irregular over pre-treatment

2 (or higher)

**Ocular**

Cataracts

Symptomatic visual loss requiring treatment or interfering with function

3 (or higher)

Glaucoma

Increase in intraocular pressure with retinal changes

2 (or higher)

**Musculoskeletal**

Osteoporosis or fracture

Symptomatic, interfering with activities of daily living

 

Avascular necrosis

Symptomatic, interfering with function

2 (or higher)

Myopathy

Symptomatic, interfering with function

2 (or higher)

**Miscellaneous**

Immunosuppression

Severe, requiring treatment withdrawal

 

Impaired healing

Symptomatic, interfering with activities of daily living

 

Growth retardation

 

 

## Hydroxychloroquine

Only valid for adult patients.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Muscle weakness

Symptomatic and interfering with function

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Neuropathy - motor

Objective weakness interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

Vision - cornea or retina

Symptomatic corneal or retinal changes present

1 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

## Methotrexate

Only valid for adult patients.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Cardiovascular**

Pericardial effusion or pericarditis

Pericarditis (pericardial rub, ECG changes or chest pain)

2 (or higher)

Thrombosis or embolism

Requiring anticoagulant therapy

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased, and symptoms don't improve with at least 2 of the following measures:

1.  reduction of the methotrexate dose
2.  folinic acid or folic acid supplementation
3.  switching from oral to intramuscular dosing
4.  dividing the methotrexate dose over 12 hours

A minimum of 3 doses of methotrexate should have been trialled

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Musculoskeletal**

Osteonecrosis  
(avascular necrosis)

Symptomatic and interfering with function

2 (or higher)

Osteoporosis

Symptomatic and requiring treatment

3 (or higher)

**Neurology or senses**

Decreased level of consciousness

Somnolence or sedation interfering with function but not interfering with activities of daily living

2 (or higher)

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

Hearing

Tinnitus or hearing loss not requiring hearing aid or treatment

2 (or higher)

Mood alteration

Moderate mood alteration interfering with function but not interfering with activities of daily living

2 (or higher)

Seizure(s)

Seizures in which consciousness is altered

3 (or higher)

Vision

Symptomatic and interfering with function but not interfering with activities of daily living

2 (or higher)

**Pulmonary**

Cough (severe)

Severe cough or coughing spasm, poor control or unresponsive to treatment. Evidence of reversal on cessation of treatment.

3 (or higher)

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary fibrosis

Respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

Pulmonary symptoms - new or worsening (probable drug-induced pneumonitis)

Development of syndrome consistent with drug-induced pneumonitis (for example, cough, dyspnoea, fever, hypoxaemia) with lung infiltrates on imaging  
(refer Searles McKendry criteria)

 

**Renal**

Haematuria

Macroscopic (or dipstick +++) confirmed on 2 separate occasions

2 (or higher)

Renal impairment

Creatinine > 1.5 ULN or creatinine clearance < 30 mL per min

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Nodulosis (following introduction of methotrexate therapy)

Development of multiple new nodules causing significant local pressure symptoms and distress to patient

 

Secondary malignancy

Secondary malignancy present

4

## Azathioprine

Only valid for adult patients.

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

Neutropenia

Total neutrophils < 1.0 x 109 per L

3 (or higher)

**Dermatology or skin**

Alopecia

Pronounced hair loss

2 (or higher)

Rash or desquamation

Scattered macular or papular eruption or erythema with pruritis or other associated symptoms covering < 50% of body surface or localised desquamation or other lesions covering < 50% of body

2 (or higher)

**Gastrointestinal**

Diarrhoea

Increase of 4-6 stools per day over pre-treatment

2 (or higher)

Nausea

Oral intake significantly decreased

2 (or higher)

Pancreatitis

Abdominal pain with pancreatic enzyme elevation

3 (or higher)

Stomatitis

Painful erythema, oedema or ulcers but able to eat or swallow

2 (or higher)

Vomiting

2 or more episodes per 24 hours over pre-treatment

2 (or higher)

**Hepatic**

Bilirubin

\> 1.5 x ULN

2 (or higher)

Transaminases

ALT or AST > 2.5 x ULN or ALT or AST > 1.5 x ULN on 3 occasions over a 3-month period

2 (or higher)

Ç Serum alkaline phosphatase

2.5 x ULN

2 (or higher)

**Neurology or senses**

Headaches (severe)

Severe pain; pain or analgesics severely interfere with activities of daily living

3 (or higher)

**Pulmonary**

Pneumonitis or pulmonary infiltrates

Radiographic changes, respiratory function test abnormalities and requiring steroids or diuretics

2 (or higher)

**Other**

Allergic reaction

Urticaria, drug fever > 38 °C or bronchospasm

2 (or higher)

Fatigue, malaise

Severe, loss of ability to perform some activities

3 (or higher)

Fever (in the absence of neutropenia)

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Infection

Severe, systemic infection, requiring IV antimicrobial treatment or hospitalisation

3 (or higher)

Secondary malignancy

Secondary malignancy present

4

## Mycophenolate

Adverse event

Brief description of minimum grade

NIH common toxicity criteria grade

**Gastrointestinal**

Gastric irritation or ulcer

Requiring medical management

2 (or higher)

Nausea

Oral intake significantly reduced

2 (or higher)

Vomiting

2 or more episodes in 24 hours over pre-treatment

2 (or higher)

Diarrhoea

Increase of more than 4 stools per day over pre-treatment, or incontinence

2 (or higher)

**Central nervous system**

Altered mental status

Confusion, memory impairment, lethargy or somnolence causing inability to perform usual social and functional activities

3 (or higher)

Dizziness

Moderate unsteadiness; limiting activities of daily living

2 (or higher)

Tremor

Moderate symptoms; limiting activities of daily living

2 (or higher)

Insomnia

Frequent insomnia interfering with activities of daily living

3 (or higher)

**Dermatological**

Infection

Oral intervention indicated (e.g. antibiotic, antifungal, antiviral)

2 (or higher)

Rash

Rash with associated symptoms over less than 50% of body surface

2 (or higher)

**Blood or bone marrow**

Anaemia

Haemoglobin < 80 g per L

3 (or higher)

Leukopenia

Total WCC < 3 x 109 per L

2 (or higher)

Thrombocytopenia

Platelets < 50 x 109 per L

3 (or higher)

**Pulmonary**

Infection

Oral intervention indicated (e.g. antibiotic, antifungal, antiviral)

2 (or higher)

**Body as a whole**

Sepsis

Life-threatening consequences

4

Infection

Oral intervention indicated (e.g. antibiotic, antifungal, antiviral)

2 (or higher)

Headache

Moderate pain; limiting activities of daily living

2 (or higher)

Fever

Body temp > 39 °C (oral or tympanic)

2 (or higher)

Abdominal pain

Severe pain, analgesia interfering with activities of daily living

3 (or higher)

Neoplasm

New malignancy present

4
